Do Moleculin Biotech Inc. (NASDAQ: MBRX) Fit In A Value Investing Philosophy?

0
35

Empery Asset Management LP recently announced the acquisition of new stake in Moleculin Biotech Inc. (NASDAQ:MBRX). This fresh investment now brings its stake to 6.21% valued currently at $3.63 million. In addition, The Vanguard Group, Inc. raised its holdings by 36698.0 to 2.64 million shares. And Renaissance Technologies LLC has lifted its position by 25.47% or 0.26 million shares – to 1.26 million shares.

With over 1.62 million Moleculin Biotech Inc. (MBRX) shares trading Tuesday and a closing price of $1.14 on the day, the dollar volume was approximately $1.85 million. The shares have shown a negative weekly performance of -14.29% and its price on 07/28/20 lost nearly -3.39%. Currently, there are 49.93M common shares owned by the public and among those 45.93M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for MBRX have a consensus price objective of $3.33. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $2.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Moleculin Biotech Inc. stock is 1.70 for the next 12 months. But an upside of 77.2% will see the stock hit the forecast high price target while mean target price for the stock is $3.00.

Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 79,227 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 19,292 shares.

The top 3 mutual fund holders in Moleculin Biotech Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.97 million shares of the company’s stock, all valued at over $0.94 million. The company sold -0.46 million shares recently to bring their total holdings to about 1.61% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.49% of the shares outstanding.

Shares of Moleculin Biotech Inc. (NASDAQ: MBRX) opened at $1.15, down -$0.03 from a prior closing price of $1.18. However, the script later closed the day at $1.14, down -3.39%. The company’s stock has a 5-day price change of -14.29% and 100.21% over the past three months. MBRX shares are trading 24.58% year to date (YTD), with the 12-month market performance down to -5.79% lower. It has a 12-month low price of $0.32 and touched a high of $1.97 over the same period. Currently, 1.62 million shares have been traded, compared to an average intraday trading volume of 4.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.60%, 8.04%, and 18.90% respectively.

Institutional ownership of Moleculin Biotech Inc. (NASDAQ: MBRX) shares accounts for 20.40% of the company’s 49.93M shares outstanding. Mutual fund holders own 10.89%, while other institutional holders and individual stakeholders account for 3.20% and 10.76% respectively.

It has a market capitalization of $71.18M and a beta (3y monthly) value of 2.47. The earnings-per-share (ttm) stands at -$0.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.94% over the week and 9.91% over the month.

Analysts forecast that Moleculin Biotech Inc. (MBRX) will achieve an EPS of -$0.09 for the current quarter, -$0.09 for the next quarter and -$0.37 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.09 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.03 a year ago. Earnings per share for the fiscal year are expected to increase by 29.30%, and -23.30% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Moleculin Biotech Inc. (MBRX) as a “Strong Buy” at a consensus score of 1.70. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here